{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:33:19Z","timestamp":1774949599262,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,10,27]],"date-time":"2009-10-27T00:00:00Z","timestamp":1256601600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s00296-009-1213-z","type":"journal-article","created":{"date-parts":[[2009,10,26]],"date-time":"2009-10-26T08:20:05Z","timestamp":1256545205000},"page":"33-37","source":"Crossref","is-referenced-by-count":59,"title":["One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Beh\u00e7et\u2019s disease refractory to standard immunosuppressive drugs"],"prefix":"10.1007","volume":"31","author":[{"given":"AnnaRita","family":"Giardina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Vadal\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ennio","family":"Giardina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Triolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,10,27]]},"reference":[{"key":"1213_CR1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0049-0172(98)80001-2","volume":"27","author":"VG Kaklamani","year":"1998","unstructured":"Kaklamani VG, Variopoulos G, Kaklamanis PG (1998) Beh\u00e7et\u2019s disease. Semin Arthritis Rheum 27:197\u2013217","journal-title":"Semin Arthritis Rheum"},{"key":"1213_CR2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/08830189709116845","volume":"14","author":"RB Nussenblatt","year":"1997","unstructured":"Nussenblatt RB (1997) Uveitis in Beh\u00e7et\u2019s disease. Int Rev Immunol 14:67\u201379","journal-title":"Int Rev Immunol"},{"key":"1213_CR3","first-page":"145","volume-title":"Beh\u00e7et\u2019s disease","author":"K Nakae","year":"1993","unstructured":"Nakae K, Masaki F, Hashimoto T, Inaba G, Mochizuki M, Sakane T (1993) Recent epidemiological features of Beh\u00e7et\u2019s disease in Japan. In: Wechsler B, Godeau P (eds) Beh\u00e7et\u2019s disease. Excerpta Medica, Amsterdam, pp 145\u2013151"},{"key":"1213_CR4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3349\/ymj.1997.38.6.411","volume":"38","author":"CC Zouboulis","year":"1997","unstructured":"Zouboulis CC, K\u00f6tter I, Djawari D et al (1997) Epidemiological features of Adamantiades-Beh\u00e7et\u2019s disease in Germany and in Europe. Yonsei Med J 38:411\u2013422","journal-title":"Yonsei Med J"},{"key":"1213_CR5","first-page":"165","volume-title":"Beh\u00e7et\u2019s disease","author":"N Dilsen","year":"1993","unstructured":"Dilsen N, Konice M, Aral O, \u00d6cal L, Inanc M, Gill A (1993) Risk factors for vital organ involvement in Beh\u00e7et\u2019s disease. In: Wechsler B, Godeau P (eds) Beh\u00e7et\u2019s disease. Excerpta Medica, Amsterdam, pp 165\u2013169"},{"key":"1213_CR6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/archopht.1970.00990040453009","volume":"84","author":"JG Mamo","year":"1970","unstructured":"Mamo JG (1970) The rate of visual loss in Beh\u00e7et\u2019s disease. Arch Ophthalmol 84:451\u2013452","journal-title":"Arch Ophthalmol"},{"key":"1213_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/01.bor.0000197995.27579.9b","volume":"18","author":"N Pipitone","year":"2006","unstructured":"Pipitone N, Olivieri I, Cantini F, Triolo G, Salvarani C (2006) New approaches in the treatment of Adamantiades-Beh\u00e7et\u2019s diseases. Curr Opin Rheumatol 18:3\u20139","journal-title":"Curr Opin Rheumatol"},{"key":"1213_CR8","first-page":"321","volume":"23","author":"N Sayinalp","year":"1996","unstructured":"Sayinalp N, Ozcebe OI, Ozdenir O, Haznedaroglu IC, Dundar S, Kirazli S (1996) Cytokines in Beh\u00e7et\u2019s disease. J Rheumatol 23:321\u2013322","journal-title":"J Rheumatol"},{"key":"1213_CR9","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/1529-0131(199909)42:9<1967::AID-ANR24>3.0.CO;2-Z","volume":"42","author":"MA Frassanito","year":"1999","unstructured":"Frassanito MA, Dammacco R, Cafforio P, Dammacco F (1999) Th1 polarization of the immune response in Beh\u00e7et\u2019s disease: a putative role of interleukin-12. Arthritis Rheum 42:1967\u20131974","journal-title":"Arthritis Rheum"},{"key":"1213_CR10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1136\/ard.61.5.459","volume":"61","author":"G Triolo","year":"2002","unstructured":"Triolo G, Accardo-Palumbo A, Dieli F, Ciccia F, Ferrante A, Giardina E, Licata G (2002) Humoral and cell mediated immune response to cow\u2019s milk proteins in Behcet\u2019s disease. Ann Rheum Dis 61:459\u2013462","journal-title":"Ann Rheum Dis"},{"key":"1213_CR11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/08830180212063","volume":"21","author":"RR Caspi","year":"2002","unstructured":"Caspi RR (2002) Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol 21:197\u2013208","journal-title":"Int Rev Immunol"},{"key":"1213_CR12","doi-asserted-by":"crossref","first-page":"R262","DOI":"10.1186\/ar785","volume":"5","author":"G Triolo","year":"2003","unstructured":"Triolo G, Accardo-Palumbo A, Dieli F, Ciccia F, Ferrante A, Giardina E, Sano CD, Licata G (2003) Vgamma9\/Vdelta2 T lymphocytes in Italian patients with Behcet\u2019s disease: evidence for expansion, and tumour necrosis factor receptor II and interleukin-12 receptor beta1 expression in active disease. Arthritis Res Ther 5:R262\u2013R268","journal-title":"Arthritis Res Ther"},{"key":"1213_CR13","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/art.21145","volume":"52","author":"M Todaro","year":"2005","unstructured":"Todaro M, Zerilli M, Triolo G, Iovino F, Patti M et al (2005) NFkB protects Beh\u00e7et\u2019s disease T cells against CD95 induced apoptosis upregulating anti apoptotic proteins. Arthritis Rheum 52:2179\u20132191","journal-title":"Arthritis Rheum"},{"issue":"9278","key":"1213_CR14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","volume":"28;358","author":"PP Sfikakis","year":"2001","unstructured":"Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behcet\u2019s disease. Lancet 28;358(9278):295\u2013296","journal-title":"Lancet"},{"key":"1213_CR15","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/ard.61.6.560","volume":"61","author":"G Triolo","year":"2002","unstructured":"Triolo G, Vadala M, Accardo-Palumbo A, Ferrante A, Ciccia F, Giardina E, Citarrella P, Lodato G, Licata G (2002) Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet\u2019s disease. Ann Rheum Dis 61:560\u2013561","journal-title":"Ann Rheum Dis"},{"key":"1213_CR16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00296-008-0606-8","volume":"29","author":"H Al-Rayes","year":"2008","unstructured":"Al-Rayes H, Al-Swallen R, Al-Balawi M et al (2008) Safety and efficacy of infliximab therapy in active Beh\u00e7et\u2019s uveitis: an open-label study. Rheumatol Int 29:53\u201357","journal-title":"Rheumatol Int"},{"key":"1213_CR17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1136\/ard.62.3.280","volume":"62","author":"G Licata","year":"2003","unstructured":"Licata G, Pinto A, Tuttolomondo A, Banco A, Ciccia F, Ferrante A, Triolo G (2003) Anti-tumor necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Beh\u00e7et\u2019s syndrome. Ann Rheum Dis 62:280\u2013281","journal-title":"Ann Rheum Dis"},{"key":"1213_CR18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/art.23345","volume":"59","author":"N Pipitone","year":"2009","unstructured":"Pipitone N, Olivieri I, Padula A et al (2009) Infliximab for the treatment of neuro-Behe\u00e7et\u2019s disease: a case series and review of the literature. Arthritis Rheum 59:285\u2013290","journal-title":"Arthritis Rheum"},{"key":"1213_CR19","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/ard.60.6.637","volume":"60","author":"PH Goossens","year":"2001","unstructured":"Goossens PH, Verburg RJ, Bredveld FC (2001) Remission of Beh\u00e7et\u2019s syndrome with tumour necrosis factor \u03b1 blocking therapy. Ann Rheum Dis 60:637","journal-title":"Ann Rheum Dis"},{"key":"1213_CR20","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1053\/gast.2001.22556","volume":"120","author":"PV Hassard","year":"2001","unstructured":"Hassard PV, Binder SW, Nelson V, Vasiliauskas EA (2001) Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet\u2019s disease: a case report. Gastroenterology 120:995\u2013999","journal-title":"Gastroenterology"},{"key":"1213_CR21","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gut.49.5.725","volume":"49","author":"SP Travis","year":"2001","unstructured":"Travis SP, Czajkowski M, McGovern DP, Watson RG, Bell AL (2001) Treatment of intestinal Behcet\u2019s syndrome with chimeric tumour necrosis factor alpha antibody. Gut 49:725\u2013728","journal-title":"Gut"},{"key":"1213_CR22","first-page":"995","volume":"335","author":"International Study Group for Beh\u00e7et\u2019s Disease","year":"1990","unstructured":"International Study Group for Beh\u00e7et\u2019s Disease (1990) Criteria for diagnosis of Beh\u00e7et\u2019s disease. Lancet 335:995\u2013999","journal-title":"Lancet"},{"key":"1213_CR23","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/rheumatology\/38.8.728","volume":"38","author":"BB Bahcta","year":"1999","unstructured":"Bahcta BB, Brennan P, James TE, Chamberlain A, Noble BA, Silman AJ (1999) Beh\u00e7et\u2019s disease: evaluation of a new instrument to measure clinical activity. Rheumatology 38:728\u2013735","journal-title":"Rheumatology"},{"key":"1213_CR24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/rheumatology\/keg453","volume":"43","author":"G Lawton","year":"2004","unstructured":"Lawton G, Bahcta BB, Chamberlain AA, Tennant A (2004) Beh\u00e7et\u2019s disease activity index. Rheumatology 43:73\u201378","journal-title":"Rheumatology"},{"key":"1213_CR25","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature (SUN) working group, Standardization of uveitis nomenclature for reporting clinical data Results of the first international workshop. Am J Ophtalmol 140:509\u2013516","journal-title":"Am J Ophtalmol"},{"key":"1213_CR26","unstructured":"Hatemi G, Silman A, Bang D, Bodaghi B et al (2008) EULAR recommendations for the management of Beh\u00e7et\u2019s disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis"},{"key":"1213_CR27","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/BF02983787","volume":"77","author":"Y Katsura","year":"2003","unstructured":"Katsura Y, Suzukawa K, Kojima H, Yoshida C, Shimizu S, Mukai H, Hasegawa Y, Imagawa S, Mori N, Nagasawa T (2003) Cytotoxic T-cell lymphoma arising in Behcet disease. Int J Hematol 77:282\u2013285","journal-title":"Int J Hematol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-009-1213-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-009-1213-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-009-1213-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T11:18:36Z","timestamp":1559042316000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-009-1213-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,27]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["1213"],"URL":"https:\/\/doi.org\/10.1007\/s00296-009-1213-z","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,27]]}}}